Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
The company plans to use the proceeds to fund the redemption of its outstanding 5.00 percent senior notes due 2020.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
Vermont-based BioTek is a privately held company that manufactures and sells life science instruments, including cell imaging systems.
Patients who enroll will have their samples tested as part of routine diagnostic care, making it easier for them to take part in clinical trials without additional testing.
The company said it will use the funding to accelerate the launch of its core isotachophoresis platform for nucleic acid sample preparation.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.